Identification of Biomarkers for Prognosis and Immunotherapy in Clear Cell Renal Cell Carcinoma

Zuhu Yu (✉ tigeruro@163.com)

University of Chinese Academy of Sciences Shenzhen Hospital(Guangming), formerly Guangming New District People's Hospital

Bin Lu

University of Chinese Academy of Sciences Shenzhen Hospital(Guangming), formerly Guangming New District People's Hospital

Hong Gao

University of Chinese Academy of Sciences Shenzhen Hospital(Guangming), formerly Guangming New District People's Hospital

Wuxing Xiang

University of Chinese Academy of Sciences Shenzhen Hospital(Guangming), formerly Guangming New District People's Hospital

Rongfang Liang

University of Chinese Academy of Sciences Shenzhen Hospital(Guangming), formerly Guangming New District People's Hospital

Tao Liang

University of Chinese Academy of Sciences Shenzhen Hospital(Guangming), formerly Guangming New District People's Hospital

Wenhui Chen

University of Chinese Academy of Sciences Shenzhen Hospital(Guangming), formerly Guangming New District People's Hospital

Jinping Liu

University of Chinese Academy of Sciences Shenzhen Hospital(Guangming), formerly Guangming New District People's Hospital

Research Article

Keywords: ccRCC, PCK1, HMGCS2, RRM2, biomarker

Posted Date: August 18th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-733571/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background: Clear cell renal cell carcinoma (ccRCC) is the dominating subtype of renal cancer with high malignancy and poor prognosis, accounts for the majority of kidney cancer deaths. We conducted this research to identify novel potential biomarkers for the prognosis and immunotherapy of ccRCC patients. We screened out differentially expressed genes (DEGs) between ccRCC tissues and adjacent normal tissues with 4 microarray series from GEO database and took function analysis of DEGs with GO and KEGG pathway. Then, we constructed PPI network and identified target genes with prognostic value in ccRCC, performed immunological correlation analysis of the candidate genes to seek potential biomarkers of immunotherapy in ccRCC.

Results: In total, 159 up-regulated genes and 223 down-regulated genes were screened out and 11 genes including TIMP1, PCK1, HMGCS2, G6PC, FBP1, ACAA1, HADH, HAO2, TGFBI, RRM2 and SUCLG1 were found to be associated with prognoses of ccRCC patients. After further screening and verification of the mRNA and protein expression, down-regulation of PCK1, HMGCS2, and up-regulation of RRM2 were significantly correlated with poorer prognoses both in overall survival and disease free survival in ccRCC. Further immunological correlation analysis showed RRM2 expression was correlated with immune infiltration and immunological checkpoint in ccRCC.

Conclusion: We identified PCK1, HMGCS2 and RRM2 as potential markers for the prognosis of ccRCC patients with bioinformatic analyses. RRM2 may plays an important role in the oncogenicity of ccRCC and is a potential target for immunotherapy of ccRCC patients.

Background

Renal cell carcinoma, which derive from renal tubular epithelial cells, is one of the most common malignant urinary tumors, with a proportion of approximately 3% of adult malignancies and close to 90% of all renal neoplasms [1, 2]. The most aggressive histological subtype of renal cancer, accounting for 75–80% of all RCC patients, is clear cell renal cell carcinoma (ccRCC), with a higher rate of metastasis and a poorer prognosis among common renal malignancies [3, 4]. Etiology and tumorigenesis of ccRCC remain indistinct, and the mechanism of occurrence, progression and metastasis of tumors refer to a mass of genes, multifarious signal pathways, and the entire genes regulatory network. Surgical resection remains the best curative option for patients with localized disease, but to the advanced tumors, systemic therapy still does not significantly improve the prognosis [4]. In recent years, the remarkable efficacy of immunotherapy in the treatment of malignant tumor has provided a new thought for the treatment of advanced renal cancer [5]. Thus, it is essential to probe into rooted molecular mechanisms of occurrence and development of ccRCC and identify potential biomarkers for early diagnosis, prognosis and precise therapy.

In the past few decades, enormous quantity of biological information has emerged with the progress of genomics and molecular biotechnology, whereas the traditional single-gene experimental research cannot meet the growing needs of tumor molecular mechanism research [6]. Fortunately, bioinformatics, the integration of biology, computer informatics and statistics, make it possible to analyze and excavate the vast biological data that has been obtained. With the assistant of bioinformatics analysis, researchers can analyze abundant gene expression data obtained by high-throughput microarray expression profile to discern key molecules in the process of oncogenesis and tumor progression, and seek for potential therapeutic targets of tumors [7, 8].

In the present study, we screened out 4 microarray series from the National Center for Biotechnology Information's (NCBI) Gene Expression Omnibus (GEO), and analyzed the series with GEO2R to acquire differentially expressed genes (DEGs) between ccRCC tissues and adjacent normal tissues. Whereafter, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis and protein-protein interaction (PPI) network analysis were implemented to understand the molecular mechanisms underlying carcinogenesis and progression of ccRCC. We further identified the hub genes with prognostic value in the gene regulatory network of ccRCC and performed the immunological correlation analysis of the candidate biomarkers to seek potential molecular targets of immunotherapy in ccRCC.

Methods

Data collection in the GEO database

We screened the mRNA microarray series containing ccRCC tissues and adjacent normal tissues in the GEO database (<https://www.ncbi.nlm.nih.gov/geo/>) and selected four gene expression datasets (GSE6344, GSE47032, GSE53757, GSE66270) for further analysis [9–14]. GSE6344 and GSE47032 each has 10 paired of ccRCC tissues and adjacent normal tissues, and the corresponding platforms are GPL96 (Affymetrix Human Genome U133A Array) and GPL5188 [Affymetrix Human Exon1.0ST Array, probe set (exon) version], respectively. Platforms of GSE53757 and GSE66270 are both GPL570 (Affymetrix Human Genome U133 Plus 2.0 Array), with 72 pairs and 14 pairs of paired specimens, respectively.

Screening and identification of DEGs

We use GEO2R, an interactive web tool that allows users to compare two or more groups of samples in a GEO series, to compare two groups of samples in the four series in order to identify the genes that are differentially expressed. Default statistical parameters were used and probe sets with vacant gene symbols or genes with more than one probe set were removed or averaged accordingly. The adjusted P-values (adj.P) < 0.01 and the |logFC| (fold change) > 2 were considered statistically significant to generate the collective DEGs in the four researches. Venn diagram was used to presented the results of the filtering.

Function enrichment analysis of DEGs

GO enrichment analysis provides the investigators structured and computable annotations regarding the functions of genes and gene products from three orientations: cellular component(CC), molecular function(MF) and biological process(BP). KEGG is an accessible database for systematic analysis of gene functions and advanced functions of biological systems from genomic and molecular level [15–17]. We exploited the DAVID (Database for Annotation, Visualization and Integrated Discovery, <https://david.ncifcrf.gov/>, version 6.8) to analyze the functions of DEGs acquired. This bioinformatic database assist the researchers to understand biological information regarding the given numbers of genes via providing a comprehensive set of functional annotation tools. FDR (false discovery rate) < 0.05 was considered statistically significant.

PPI network and module analysis

The STRING website(<https://www.string-db.org/>, version 11.0), the online database for known protein interactions, was utilized to explore the interactions of DEGs with the minimum required interaction score was 0.4. Cytoscape (version 3.8.0) was applied for visualizing molecular interaction networks and the plug-in Molecular Complex Detection (MCODE) (version 2.0.0) in Cytoscape was ran for identifying the most significant module in the PPI network. Parameters set as degree cutoff = 2, node score cutoff = 0.2, K-score = 2 and Max depth = 100. Go and KEGG analysis of the genes in the significant module were analyzed using DAVID. Statistical significance was set as FDR < 0.05.

Hub genes screening and survival analysis of candidate genes

The hub genes were identified by means of the CytoHubba in Cytoscape, the plug-in which predicts and explores important nodes and sub-networks in a given network by several topological algorithms. The hub genes were selected with degrees > 10. Subsequently, the obtained hub genes were further screened for their prognostic values through three websites: UALCAN(<http://ualcan.path.uab.edu/>), GEPIA(Gene Expression Profiling Interactive Analysis, <http://gepia.cancer-pku.cn/>) and HPA(the Human Protein Atlas, <https://www.proteinatlas.org/>) [18–20]. In all screening procedures, P < 0.05 was considered statistically significant. Results in which the expression level in the tumor was inconsistent with the prognosis were discarded.

Verification of expression levels of candidate genes

The mRNA level of candidate genes in ccRCC tissues and normal kidney tissues were verified by GEPIA. Meanwhile, CCLE (Cancer Cell Line Encyclopedia, <https://portals.broadinstitute.org/ccle/>) was utilized to inspect the variations of candidate genes in renal cancer cell lines at mRNA level [21]. Results of inconsistent changes of mRNA levels in ccRCC tissues and renal cancer cell lines were rejected. The protein expressions of candidate genes in ccRCC and paracancerous tissues were tested

using CPTAC (Clinical Proteomic Tumor Analysis Consortium) confirmatory or discovery datasets via UALCAN, and reconfirmed in the HPA website [22].

Potential target for immunotherapy

We applied two databases simultaneously to evaluate the potential of candidate genes as immunotherapeutic targets. TIMER(Tumor Immune Estimation Resource, <https://cistrome.shinyapps.io/timer/>), a tool for comprehensive analysis of tumor-infiltrating immune cells, was used for investigating the correlations of candidate genes with immune infiltration level in ccRCC and the relevance between target genes and PD-1(Programmed Cell Death 1), PDL-1(Programmed Cell Death 1 Ligand 1) and CTLA-4 [23]. When $|\text{correlation coefficient (cor)}| \geq 0.2$ and $P < 0.05$, it would be considered statistically significant. In the meanwhile, we took advantage of TISIDB(<http://cis.hku.hk/TISIDB/index.php>), an integrated repository portal for tumor-immune system interactions, to examine the relations between abundance of TILs(tumor-infiltrating lymphocytes) and expression of target gene in 28 types of humancancers [24]. The correlations between target gene and immunoinhibitors were tested moreover. Drugs targeting the target gene collected from DrugBank database were also presented. Spearman's test was used in all tests and $P < 0.05$ were considered significant.

Results

Identification of DEGs in the ccRCC

After calculation with GEO2R, the volcano plots of four selected gene expression datasets were plotted and shown in Fig. 1A. The quantities of DEGs in GSE6344, GSE47032, GSE53757, GSE66270 after further screening were 701, 1830, 1281 and 2042, respectively. There were 382 overlapped genes in the four datasets, as shown in Fig. 1B with Venn diagram, containing 159 up-regulated genes and 223 down-regulated genes in ccRCC tissues compared to adjacent normal tissues.

Functional annotations of DEGs

We performed GO and KEGG pathway analysis of the screened up-regulated genes and down-regulated genes with DAVID. The results were shown in Table 1 and Table 2. Results of Go analysis revealed that DEGs are mostly enriched in extracellular space, integral component of plasma membrane, cell surface, extracellular exosome, basolateral plasma membrane, apical plasma membrane and integral component of plasma membrane. The biological process(BP) of DEGs are enriched in response to hypoxia, regulation of immune response, angiogenesis, inflammatory response, cell adhesion, excretion, gluconeogenesis, kidney development and oxidation-reduction process. Regarding to the molecular function of DEGs, the changes are principally involved in protein homodimerization activity, protein binding, receptor binding, protease binding, receptor activity, transporter activity, heparin binding and identical protein binding. The KEGG analysis indicated that change of DEGs are engaged in focal adhesion, phagosome, HIF-1 signaling pathway, Toll-like receptor signaling pathway, rheumatoid arthritis, metabolic pathways, glycolysis/gluconeogenesis, biosynthesis of antibiotics, carbon metabolism and Tyrosine metabolism.

Table 1
The Gene ontology analysis of differentially expressed genes in the ccRCC.

Gene expression	Category	Term	Count	%	P Value	FDR
Up-regulated genes	GOTERM_CC_DIRECT	GO:0005615 ~ extracellular space	42	26.41509434	6.61E-13	1.33E-10
	GOTERM_CC_DIRECT	GO:0005576 ~ extracellular region	42	26.41509434	1.84E-10	1.85E-08
	GOTERM_CC_DIRECT	GO:0005887 ~ integral component of plasma membrane	35	22.01257862	4.02E-08	2.53E-06
	GOTERM_CC_DIRECT	GO:0009986 ~ cell surface	21	13.20754717	5.04E-08	2.53E-06
	GOTERM_CC_DIRECT	GO:0016020 ~ membrane	44	27.67295597	1.73E-07	6.94E-06
	GOTERM_BP_DIRECT	GO:0001666 ~ response to hypoxia	18	11.32075472	2.51E-13	3.52E-10
	GOTERM_BP_DIRECT	GO:0050776 ~ regulation of immune response	14	8.805031447	7.71E-09	5.40E-06
	GOTERM_BP_DIRECT	GO:0001525 ~ angiogenesis	15	9.433962264	1.40E-08	6.53E-06
	GOTERM_BP_DIRECT	GO:0006954 ~ inflammatory response	17	10.6918239	3.17E-07	8.88E-05
	GOTERM_BP_DIRECT	GO:0007155 ~ cell adhesion	18	11.32075472	8.31E-07	1.66E-04
	GOTERM_MF_DIRECT	GO:0042803 ~ protein homodimerization activity	24	15.09433962	7.35E-08	2.70E-05
	GOTERM_MF_DIRECT	GO:0005515 ~ protein binding	107	67.29559748	2.75E-07	5.06E-05
	GOTERM_MF_DIRECT	GO:0005102 ~ receptor binding	15	9.433962264	2.36E-06	2.89E-04
	GOTERM_MF_DIRECT	GO:0002020 ~ protease binding	8	5.031446541	2.73E-05	0.002516149
	GOTERM_MF_DIRECT	GO:0004872 ~ receptor activity	10	6.289308176	1.15E-04	0.00843084
Down-regulated genes	GOTERM_CC_DIRECT	GO:0070062 ~ extracellular exosome	107	48.1981982	1.60E-31	3.23E-29
	GOTERM_CC_DIRECT	GO:0016323 ~ basolateral plasma membrane	18	8.108108108	4.91E-11	4.96E-09
	GOTERM_CC_DIRECT	GO:0016324 ~ apical plasma membrane	21	9.459459459	2.94E-10	1.98E-08
	GOTERM_CC_DIRECT	GO:0005887 ~ integral component of plasma membrane	40	18.01801802	5.81E-07	2.93E-05

Gene expression	Category	Term	Count	%	P Value	FDR
	GOTERM_CC_DIRECT	GO:0005615 ~ extracellular space	37	16.66666667	3.45E-06	1.39E-04
	GOTERM_BP_DIRECT	GO:0007588 ~ excretion	10	4.504504505	6.84E-10	9.83E-07
	GOTERM_BP_DIRECT	GO:0006094 ~ gluconeogenesis	8	3.603603604	1.27E-06	7.06E-04
	GOTERM_BP_DIRECT	GO:0001822 ~ kidney development	10	4.504504505	1.47E-06	7.06E-04
	GOTERM_BP_DIRECT	GO:0001657 ~ ureteric bud development	7	3.153153153	7.84E-06	0.002816272
	GOTERM_BP_DIRECT	GO:0055114 ~ oxidation-reduction process	21	9.459459459	7.29E-05	0.01588296
	GOTERM_MF_DIRECT	GO:0005215 ~ transporter activity	13	5.855855856	9.23E-06	0.004585068
	GOTERM_MF_DIRECT	GO:0008201 ~ heparin binding	11	4.954954955	3.37E-05	0.008371823
	GOTERM_MF_DIRECT	GO:0004024 ~ alcohol dehydrogenase activity, zinc-dependent	3	1.351351351	0.002256547	0.281792451
	GOTERM_MF_DIRECT	GO:0042802 ~ identical protein binding	20	9.009009009	0.002755314	0.281792451
	GOTERM_MF_DIRECT	GO:0015301 ~ anion:anion antiporter activity	4	1.801801802	0.002834934	0.281792451

Table 2
The KEGG pathway analysis of differentially expressed genes in the ccRCC.

Category	Term	Count	%	PValue	FDR
Up-regulated genes	hsa04510:Focal adhesion	14	8.805031447	5.42E-06	5.66E-04
	hsa04145:Phagosome	12	7.547169811	7.30E-06	5.66E-04
	hsa04066:HIF-1 signaling pathway	9	5.660377358	5.59E-05	0.002888511
	hsa04620:Toll-like receptor signaling pathway	9	5.660377358	1.13E-04	0.004389804
	hsa05323:Rheumatoid arthritis	8	5.031446541	2.23E-04	0.006910849
Down-regulated genes	hsa01100:Metabolic pathways	53	23.87387387	4.88E-09	8.00E-07
	hsa00010:Glycolysis / Gluconeogenesis	9	4.054054054	4.17E-05	0.003420768
	hsa01130:Biosynthesis of antibiotics	14	6.306306306	2.30E-04	0.012594775
	hsa01200:Carbon metabolism	10	4.504504505	3.32E-04	0.013626947
	hsa00350:Tyrosine metabolism	6	2.702702703	5.28E-04	0.017325663

PPI network construction and the most significant module analysis

In order to construct the PPI network of the 382 DEGs, STRING online database and Cytoscape software were used, as shown in Fig. 1C. After calculation with MCODE, the most significant module in the network arose, as shown in Fig. 2A. Function annotations of the genes in the most significant module were also performed, shown in Fig. 2B-E. These genes are mainly enriched in endoplasmic reticulum lumen, post-translational protein modification, cellular protein metabolic process, serine-type endopeptidase activity, endopeptidase activity, and complement and coagulation cascades.

Hub genes analysis and the prognostic value assessment

We figured out the hub genes of the DEGs with degree > 10 using CytoHubba plug-in in Cytoscape and further screened the hub genes utilizing UALCAN, GEPIA and HPA for their prognostic values in ccRCC. The hub genes associated with prognoses in ccRCC and the P values of statistical analysis were listed in Table 3. A total of 11 genes including TIMP1, PCK1, HMGCS2, G6PC, FBP1, ACAA1, HADH, HAO2, TGFBI, RRM2 and SUCLG1 were found to be associated with prognoses of ccRCC patients. Five genes including CASR, SLC34A1, ALDOB, FABP1 and MYCN were found to be associated with ccRCC patients' prognoses when evaluated using UALCAN and GEPIA, but not when using HPA website. Based on the above analysis and previous researches on related genes in Pubmed literature, we choose PCK1, HMGCS2 and RRM2 for further explorations. Survival curves of PCK1, HMGCS2 and RRM2 in ccRCC patients were shown in Fig. 3. The survival analysis had shown that ccRCC patients with low expression of PCK1 or HMGCS2 have significantly poorer prognoses both in overall survival and disease free survival while high RRM2 expression was correlated with worse survival.

Table 3
The candidates of hub genes with multiple database screenings.

Hub gene	Full name	Degree	UALCAN P value	GEPIA P value		Prognostic value in HPA	Expression level in ccRCC tissues	Expression level in renal cancer cell lines
				OS	DS			
TIMP1	Tissue Inhibitor Of Metalloproteinases	36	< 0.0001	6.80E-07	3.70E-05	Positive	Up	Up
CASR	Calcium Sensing Receptor	25	0.0066	0.027	0.009	Negative	Down	Down
PCK1	Phosphoenolpyruvate Carboxykinase 1	20	0.00062	1.10E-06	0.00091	Positive	Down	Down
HMGCS2	3-Hydroxy-3-Methylglutaryl-CoA Synthase 2	20	< 0.0001	3.90E-05	0.00021	Positive	Down	Down
SLC34A1	Solute Carrier Family 34 Member 1	17	0.0025	9.30E-06	0.00011	Negative	Down	Down
ALDOB	Fructose-Bisphosphate Aldolase B	17	0.00039	3.70E-06	0.00021	Negative	Down	Down
FABP1	Fatty Acid Binding Protein 1	17	0.045	0.00057	0.036	Negative	Down	Down
G6PC	Glucose-6-Phosphatase Catalytic Subunit 1	16	< 0.0001	7.50E-11	3.20E-08	Positive	Down	Down
FBP1	Fructose-Bisphosphatase 1	15	< 0.0001	1.90E-11	7.90E-09	Positive	Down	Down
ACAA1	Acetyl-CoA Acyltransferase 1	14	0.01	7.00E-04	0.0015	Positive	Down	Up
HADH	Hydroxyacyl-CoA Dehydrogenase	13	0.00012	5.30E-08	9.30E-06	Positive	Down	Up
HAO2	Hydroxyacid Oxidase 2	13	< 0.0001	2.00E-07	5.00E-07	Positive	Down	Down
TGFB1	Transforming Growth Factor Beta Induced	11	0.0025	0.0019	0.0013	Positive	Up	Up
MYCN	MYCN Proto-Oncogene, BHLH Transcription Factor	11	0.0001	1.50E-05	0.035	Negative	Down	Down
RRM2	Ribonucleotide Reductase Regulatory Subunit M2	11	< 0.0001	0.021	0.047	Positive	Up	Up
SUCLG1	Succinate-CoA Ligase GDP/ADP-Forming Subunit Alpha	11	0.00051	2.60E-05	6.00E-04	Positive	Down	Up

Confirmation of the mRNA and protein expression of 3 candidate genes

We analyzed the mRNA expression levels of candidate genes in ccRCC tissues and renal cancer cell lines using GEPIA and CCLE, respectively. As shown in Table 3, 13 genes including TIMP1, CASR, PCK1, HMGCS2, SLC34A1, ALDOB, FABP1, G6PC, FBP1, HAO2, TGFBI, MYCN, RRM2 acquired accordant results in ccRCC tissues and renal cancer cell lines regarding to the mRNA expression. The mRNA levels of PCK1, HMGCS2 and RRM2 in ccRCC tissues and renal cancer cell lines were shown in Fig. 4. PCK1 and HMGCS2 are down-regulated both in ccRCC tissues and kidney cancer cell lines while RRM2 is up-regulated. These genes were also found to be associated with pathological stages of ccRCC patients, as shown in Fig. 4B. The protein expression of target genes were inspected with CPTAC datasets and HPA immunohistochemical staining. As shown in Fig. 5, protein expression of RRM2 in ccRCC tissues is higher than normal tissues, while PCK1 and HMGCS2 are down-regulated in cancer tissues.

RRM2 expression was correlated with immune infiltration and immunological checkpoint in ccRCC

We further excavated the relationships between the expressions of candidate genes and tumor immune infiltration to seek potential targets for immunotherapy of ccRCC patients. With TIMER analysis, we found RRM2 expression is positively correlated to infiltration levels of immune cells, containing B cells ($\text{cor} = 0.377$, $P < 0.001$), CD8 + T cells ($\text{cor} = 0.209$, $P < 0.001$), macrophage ($\text{cor} = 0.272$, $P < 0.001$), neutrophil ($\text{cor} = 0.37$, $P < 0.001$) and dendritic cells ($\text{cor} = 0.418$, $P < 0.001$), while no significant correlations were observed as to PCK1 and HMGCS2 (Fig. 6A). Furthermore, the relevance between candidate genes and PD-1 (CD274), PDL-1 (PDCD1) and CTLA4 expression were explored and the results displayed low expression of HMGCS2 is associated with CTLA4 ($\text{cor} = 0.203$, $P < 0.001$) while RRM2 expression is positively linked to PDL-1 ($\text{cor} = 0.363$, $P < 0.001$) and CTLA4 ($\text{cor} = 0.343$, $P < 0.001$) (Fig. 6B). Subsequently, we applied TISIDB website to verify the correlation between RRM2 and abundance of tumor-infiltrating lymphocytes (TILs) across 28 types of human heterogeneous cancers. The results revealed that RRM2 significantly correlated with abundance of activated CD8 T cells (Act_CD8, $\rho = 0.427$, $P < 0.001$), central memory CD8 T cells (Tcm_CD8, $\rho = 0.462$, $P < 0.001$), activated CD4 T cells (Act_CD4, $\rho = 0.762$, $P < 0.001$), Type 2 T helper cells (Th2, $\rho = 0.45$, $P < 0.001$), memory B cells (Mem_B, $\rho = 0.474$, $P < 0.001$), activated dendritic cells (Act_DC, $\rho = 0.451$, $P < 0.001$) in ccRCC (Fig. 7A-B). Relations between immunoinhibitors and RRM2 expression in ccRCC displayed that RRM2 correlated with expressions of CD96 ($\rho = 0.433$, $P < 0.001$), LAG3 ($\rho = 0.48$, $P < 0.001$), LGALS9 ($\rho = 0.413$, $P < 0.001$), PDCD1 ($\rho = 0.4$, $P < 0.001$) and TIGIT ($\rho = 0.462$, $P < 0.001$) (Fig. 7C-D). Drugs targeting RRM2 collected from DrugBank database were Cladribine, Imexon, Gallium nitrate, motexafin gadolinium and GTI 2040, as shown in Fig. 6C.

Discussion

ccRCC is the most common pathological subtype of renal cell carcinoma, with high malignancy, easy metastasis and poor prognosis, accounting for the majority of kidney cancer deaths. Despite localized renal cancer can be cured by nephrectomy, up to 30% patients with localized tumors ultimately develop recurrence and metastasis [25, 26]. With regard to the patients who have lost the opportunity for surgery, systemic treatment encompassing targeted therapy and immunotherapy is primary approach [27, 28]. Until now, mutations of certain genes such as VHL, PBRM1, SETD2, BAP1, have been found to be related to the oncogenic driving events of ccRCC, but the contributions of their mutations in the tumorigenesis and progression of ccRCC and their values as prognostic biomarkers are still not entirely clear [29, 30]. With the extensive applications of genomics technology, researchers have gained access to vast amounts of genetic data. Accordingly, bioinformatics emerged and helped researchers to dig out vital information in the gene regulatory networks of diversified cancers from abundant biological data.

In this research, we combined four mRNA microarray series which containing 106 pairs of ccRCC tissues and adjacent normal tissues from GEO database to obtain the significant DEGs in ccRCC. The results showed that 159 and 223 genes are up-regulated or down-regulated by more than four times in ccRCC, respectively. Subsequently, GO analysis of the DEGs indicated that they are principally involved in response to hypoxia, regulation of immune response, angiogenesis, inflammatory response, cell adhesion, excretion, gluconeogenesis. The KEGG analysis also showed that the DEGs mainly participate in focal adhesion, HIF-1 signaling pathway, Toll-like receptor signaling pathway, metabolic pathways, glycolysis/gluconeogenesis. The results of functional annotation of DEGs, on the other hand, suggested that many classical metabolic pathways are

reprogrammed in order to empower frantic proliferation of cancer cells in ccRCC, as previous studies have revealed [31, 32]. After construction of protein-protein interaction network of DEGs, we used CytoHubba to identify the hub genes with degree > 10 and further screened the hub genes to obtain candidate genes related with the prognoses of ccRCC by synthesizing the results of UALCAN, GEPIA and HPA. The results showed that TIMP1, PCK1, HMGCS2, G6PC, FBP1, ACAA1, HADH, HAO2, TGFBI, RRM2 and SUCLG1 are of prognostic significance in ccRCC patients, which were consistent with results of previous researches [33–37]. Whereafter, we verified the mRNA and protein expression of these genes in different ways, thus obtained three target genes, namely PCK1, HMGCS2 and RRM2. Survival analysis with three websites indicated that low expression of PCK1 or HMGCS2 and high expression of RRM2 have significantly correlated to poorer prognoses in ccRCC patients regardless of overall survival or disease free survival. This result hinted that PCK1, HMGCS2 and RRM2 could be potential prognostic biomarkers for ccRCC patients. Furthermore, we investigated the relationships between target genes and immune infiltration and immunological checkpoints in ccRCC emphatically. Analysis of TIMER showed that RRM2 expression is related to infiltration levels of B cells, CD8 + T Cells, macrophage, neutrophil and dendritic cells, as well as the expression of PDL-1 and CTLA4. The results were almost the same when analysing with TISIDB website, suggesting that RRM2 plays an important role in the occurrence and progression of ccRCC and is a potential target for immunotherapy of ccRCC patients.

PCK1(Phosphoenolpyruvate Carboxykinase 1) is the first rate-limiting enzyme of gluconeogenesis in cytoplasm, catalyzing the transformation from oxaloacetate to phosphoenolpyruvate. The isozyme is PCK2, located in mitochondria, catalyzes the same reaction. Studies have found that PCK1 is increased in gastric cancer, colon carcinoma, and tumor-repopulating cells from liver cancer, melanoma and lymphoma [38–40]. However, the expression of PCK1 was also found down-regulated in hepatocellular carcinoma and renal cancer, and low expression of this gene is related to worse survival in hepatocellular carcinoma patients [35, 41–43]. HMGCS2 (3-Hydroxy-3-Methylglutaryl-CoA Synthase 2) encodes a rate-limiting enzyme that catalyzes the first reaction of ketogenesis in mitochondrial. Researchers have discovered that HMGCS2 is reduced in colorectal cancer, prostate cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma and correlated with the prognoses of patients in these cancers [44–47]. Herein, we discovered both PCK1 and HMGCS2 are reduced in ccRCC and correlated to the prognoses of ccRCC patients. All these discoveries indicated that cancer cells have different metabolic pathways compared to normal cells and the metabolic rewiring appears to be advantageous for cancer proliferation and progression [48]. Notably, ccRCC is one of the most studied malignancies characterized by metabolic reprogramming [31]. Such alterations of metabolism in ccRCC have provided us new thoughts for the exploitation of new targets for oncotherapy [49, 50].

RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) is one of the two subunits of Ribonucleotide reductase (RR), which is the rate-limiting enzyme catalyzing the formation of deoxyribonucleotides from ribonucleotides, playing a pivotal role in DNA replication and repair. Different from the constant expression of RRM1 throughout the whole cell life, RRM2 expression changes dynamically with stimulus [51]. Considerable researches have demonstrated that RRM2 is dysregulated in multiple cancer types, including liver cancer, breast cancer, lung adenocarcinoma and glioblastoma [52–56]. As a tumor promotor, RRM2 enhances the proliferation, invasion of cancer cells and the resistance to chemotherapeutic drugs, could become the predictor for chemosensitivity and prognosis [57]. In this study, we discovered the expression of RRM2 in ccRCC is significantly increased, and patients with high expression had relative poor prognosis, which was consistent with previous results in other cancer types, suggesting that it could be a promising biomarker for the prognostic assessment for ccRCC patients. Additionally, we also found a significant correlation between RRM2 and immune cell infiltration and immunological checkpoints, suggesting that RRM2 may plays an important role in immune response of ccRCC. Numerous studies have shown that ccRCC is an immune tumor with a synergistic effect of angiogenesis and immuno-suppression [58]. Combination of antiangiogenics and targeted immunotherapy to overcome resistance has been proposed as an option in first line treatment of advanced ccRCC currently [59–60]. Our findings revealed that RRM2 is probably to be a new oncogene involved in the immune regulation mechanism and promising biomarker for ccRCC immunotherapy.

Conclusion

We screened four datasets from the GEO database and identified potential biomarkers of ccRCC with multiple bioinformatic analyses and websites. PCK1, HMGCS2 and RRM2 were identified as potential biomarkers for the prognosis of ccRCC patients

and RRM2 may plays an important role in the oncogenicity of ccRCC and is a potential target for immunotherapy of ccRCC patients.

Abbreviations

ccRCC: clear cell renal cell carcinoma

DEGs: differentially expressed genes

GEO: Gene Expression Omnibus

GO: Gene Ontology

KEGG: Kyoto Encyclopedia of Genes and Genomes

PPI: protein-protein interaction

NCBI: National Center for Biotechnology Information

DAVID: Database for Annotation, Visualization and Integrated Discovery

FDR: false discovery rate

GEPIA: Gene Expression Profiling Interactive Analysis

HPA: Human Protein Atlas

CCLC: Cancer Cell Line Encyclopedia

TIMER: Tumor Immune Estimation Resource

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

The datasets analysed during the current study are available in the following websites:

<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6344>

<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE47032>

<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE53757>

<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE66270>

The data generated during the current study are uploaded in the related files.

Competing interests

The authors declare that they have no competing interests.

Funding

The work of this article was supported by a grant from the [Scientific Research Project](#) of Health System of Guangming District, Shenzhen(No.2020R01034).

Authors' contributions

Zuhu Yu designed this research and wrote the manuscript, Bin Lu and Hong Gao completed the data analysis, Wuxing Xiang and Rongfang Liang contributed proofreading of article, Tao Liang and Wenhui Chen contributed data filtering, Jinping Liu provided suggestions for this research. All authors reviewed the manuscript.

Acknowledgements

Not applicable.

References

1. Cohen HT, McGovern FJ: **Renal-cell carcinoma**. *N Engl J Med* 2005, **353**(23):2477-2490.
2. Linehan WM, Ricketts CJ: **The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications**. *Nat Rev Urol* 2019, **16**(9):539-552.
3. Cairns P: **Renal cell carcinoma**. *Cancer Biomark* 2010, **9**(1-6):461-473.
4. Gray RE, Harris GT: **Renal Cell Carcinoma: Diagnosis and Management**. *Am Fam Physician* 2019, **99**(3):179-184.
5. Deleuze A, Saout J, Dugay F, Peyronnet B, Mathieu R, Verhoest G, Bensalah K, Crouzet L, Laguerre B, Belaud-Rotureau MA *et al*: **Immunotherapy in Renal Cell Carcinoma: The Future Is Now**. *Int J Mol Sci* 2020, **21**(7).
6. Tao Z, Shi A, Li R, Wang Y, Wang X, Zhao J: **Microarray bioinformatics in cancer- a review**. *Journal of BUON : official journal of the Balkan Union of Oncology* 2017, **22**(4):838-843.
7. Holtsträter C, Schrörs B, Bukur T, Löwer M: **Bioinformatics for Cancer Immunotherapy**. *Methods in molecular biology (Clifton, NJ)* 2020, **2120**:1-9.
8. Canzoneri R, Lacunza E, Abba MC: **Genomics and bioinformatics as pillars of precision medicine in oncology**. *Medicina* 2019, **79**(Spec 6/1):587-592.
9. Edgar R, Domrachev M, Lash AE: **Gene Expression Omnibus: NCBI gene expression and hybridization array data repository**. *Nucleic Acids Res* 2002, **30**(1):207-210.
10. Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN, Wu KJ, Luxon BA, Sinha M, Parker AS *et al*: **Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma**. *Clin Cancer Res* 2007, **13**(16):4740-4749.
11. Valletti A, Gigante M, Palumbo O, Carella M, Divella C, Sbisa E, Tullo A, Picardi E, D'Erchia AM, Battaglia M *et al*: **Genome-wide analysis of differentially expressed genes and splicing isoforms in clear cell renal cell carcinoma**. *PLoS One* 2013, **8**(10):e78452.
12. von Roemeling CA, Radisky DC, Marlow LA, Cooper SJ, Grebe SK, Anastasiadis PZ, Tun HW, Copland JA: **Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4**. *Cancer Res* 2014, **74**(17):4796-4810.

13. Wotschofsky Z, Gummlich L, Liep J, Stephan C, Kilic E, Jung K, Billaud JN, Meyer HA: **Integrated microRNA and mRNA Signature Associated with the Transition from the Locally Confined to the Metastasized Clear Cell Renal Cell Carcinoma Exemplified by miR-146-5p.** *PLoS One* 2016, **11**(2):e0148746.
14. Liep J, Kilic E, Meyer HA, Busch J, Jung K, Rabien A: **Cooperative Effect of miR-141-3p and miR-145-5p in the Regulation of Targets in Clear Cell Renal Cell Carcinoma.** *PLoS One* 2016, **11**(6):e0157801.
15. The Gene Ontology C: **The Gene Ontology Resource: 20 years and still GOing strong.** *Nucleic Acids Res* 2019, **47**(D1):D330-d338.
16. Kanehisa M: **The KEGG database.** *Novartis Found Symp* 2002, **247**:91-101; discussion 101-103, 119-128, 244-152.
17. Kanehisa M, Goto S: **KEGG: kyoto encyclopedia of genes and genomes.** *Nucleic Acids Res* 2000, **28**(1):27-30.
18. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, Varambally S: **UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses.** *Neoplasia* 2017, **19**(8):649-658.
19. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z: **GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses.** *Nucleic Acids Res* 2017, **45**(W1):W98-W102.
20. Uhlen M, Zhang C, Lee S, Sjostedt E, Fagerberg L, Bidkhor G, Benfeitas R, Arif M, Liu Z, Edfors F *et al*: **A pathology atlas of the human cancer transcriptome.** *Science* 2017, **357**(6352).
21. Ghandi M, Huang FW, Jane-Valbuena J, Kryukov GV, Lo CC, McDonald ER, 3rd, Barretina J, Gelfand ET, Bielski CM, Li H *et al*: **Next-generation characterization of the Cancer Cell Line Encyclopedia.** *Nature* 2019, **569**(7757):503-508.
22. Chen F, Chandrashekar DS, Varambally S, Creighton CJ: **Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers.** *Nat Commun* 2019, **10**(1):5679.
23. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS: **TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells.** *Cancer Res* 2017, **77**(21):e108-e110.
24. Ru B, Wong CN, Tong Y, Zhong JY, Zhong SSW, Wu WC, Chu KC, Wong CY, Lau CY, Chen I *et al*: **TISIDB: an integrated repository portal for tumor-immune system interactions.** *Bioinformatics* 2019, **35**(20):4200-4202.
25. Wolff I, May M, Hoschke B, Zigeuner R, Cindolo L, Hutterer G, Schips L, De Cobelli O, Rocco B, De Nunzio C *et al*: **Do we need new high-risk criteria for surgically treated renal cancer patients to improve the outcome of future clinical trials in the adjuvant setting? Results of a comprehensive analysis based on the multicenter CORONA database.** *Eur J Surg Oncol* 2016, **42**(5):744-750.
26. Meskawi M, Sun M, Trinh QD, Bianchi M, Hansen J, Tian Z, Rink M, Ismail S, Shariat SF, Montorsi F *et al*: **A review of integrated staging systems for renal cell carcinoma.** *Eur Urol* 2012, **62**(2):303-314.
27. Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A *et al*: **Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.** *N Engl J Med* 2016, **375**(23):2246-2254.
28. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS *et al*: **Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.** *J Clin Oncol* 2005, **23**(1):133-141.
29. Cancer Genome Atlas Research N: **Comprehensive molecular characterization of clear cell renal cell carcinoma.** *Nature* 2013, **499**(7456):43-49.
30. Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, Leng N, Pavia-Jimenez A, Wang S, Yamasaki T, Zhrebker L, Sivanand S, Spence P *et al*: **BAP1 loss defines a new class of renal cell carcinoma.** *Nat Genet* 2012, **44**(7):751-759.
31. Hakimi AA, Reznik E, Lee CH, Creighton CJ, Brannon AR, Luna A, Aksoy BA, Liu EM, Shen R, Lee W *et al*: **An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma.** *Cancer Cell* 2016, **29**(1):104-116.
32. Lameirinhas A, Miranda-Goncalves V, Henrique R, Jeronimo C: **The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma.** *Genes (Basel)* 2019, **10**(4).
33. Shi SN, Qin X, Wang S, Wang WF, Zhu YF, Lin Y, Zhou ZL, Shi BK, Liu XG: **Identification of potential novel differentially-expressed genes and their role in invasion and migration in renal cell carcinoma.** *Aging (Albany NY)* 2020, **12**(10):9205-

34. Xu WH, Xu Y, Tian X, Anwaier A, Liu WR, Wang J, Zhu WK, Cao DL, Wang HK, Shi GH *et al*: **Large-scale transcriptome profiles reveal robust 20-signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma.** *J Cell Mol Med* 2020, **24**(16):9012-9027.
35. Li B, Qiu B, Lee DS, Walton ZE, Ochocki JD, Mathew LK, Mancuso A, Gade TP, Keith B, Nissim I *et al*: **Fructose-1,6-bisphosphatase opposes renal carcinoma progression.** *Nature* 2014, **513**(7517):251-255.
36. Xiao W, Wang X, Wang T, Chen B, Xing J: **HAO2 inhibits malignancy of clear cell renal cell carcinoma by promoting lipid catabolic process.** *J Cell Physiol* 2019, **234**(12):23005-23016.
37. Du GW, Yan X, Chen Z, Zhang RJ, Tuoheti K, Bai XJ, Wu HH, Liu TZ: **Identification of transforming growth factor beta induced (TGFBI) as an immune-related prognostic factor in clear cell renal cell carcinoma (ccRCC).** *Aging (Albany NY)* 2020, **12**(9):8484-8505.
38. Li Y, Zhang M, Dorfman RG, Pan Y, Tang D, Xu L, Zhao Z, Zhou Q, Zhou L, Wang Y *et al*: **SIRT2 Promotes the Migration and Invasion of Gastric Cancer through RAS/ERK/JNK/MMP-9 Pathway by Increasing PEPCK1-Related Metabolism.** *Neoplasia* 2018, **20**(7):745-756.
39. Montal ED, Dewi R, Bhalla K, Ou L, Hwang BJ, Ropell AE, Gordon C, Liu WJ, DeBerardinis RJ, Sudderth J *et al*: **PEPCK Coordinates the Regulation of Central Carbon Metabolism to Promote Cancer Cell Growth.** *Mol Cell* 2015, **60**(4):571-583.
40. Li Y, Luo S, Ma R, Liu J, Xu P, Zhang H, Tang K, Ma J, Zhang Y, Liang X *et al*: **Upregulation of cytosolic phosphoenolpyruvate carboxykinase is a critical metabolic event in melanoma cells that repopulate tumors.** *Cancer Res* 2015, **75**(7):1191-1196.
41. Liu MX, Jin L, Sun SJ, Liu P, Feng X, Cheng ZL, Liu WR, Guan KL, Shi YH, Yuan HX *et al*: **Metabolic reprogramming by PCK1 promotes TCA cataplerosis, oxidative stress and apoptosis in liver cancer cells and suppresses hepatocellular carcinoma.** *Oncogene* 2018, **37**(12):1637-1653.
42. Tuo L, Xiang J, Pan X, Hu J, Tang H, Liang L, Xia J, Hu Y, Zhang W, Huang A *et al*: **PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27(Kip1) axis.** *J Exp Clin Cancer Res* 2019, **38**(1):50.
43. Khan MW, Biswas D, Ghosh M, Mandloi S, Chakrabarti S, Chakrabarti P: **mTORC2 controls cancer cell survival by modulating gluconeogenesis.** *Cell Death Discov* 2015, **1**:15016.
44. Zou K, Hu Y, Li M, Wang H, Zhang Y, Huang L, Xie Y, Li S, Dai X, Xu W *et al*: **Potential Role of HMGCS2 in Tumor Angiogenesis in Colorectal Cancer and Its Potential Use as a Diagnostic Marker.** *Can J Gastroenterol Hepatol* 2019, **2019**:8348967.
45. Wan S, Xi M, Zhao HB, Hua W, Liu YL, Zhou YL, Zhuo YJ, Liu ZZ, Cai ZD, Wan YP *et al*: **HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer.** *Pathol Res Pract* 2019, **215**(8):152464.
46. Wang YH, Liu CL, Chiu WC, Twu YC, Liao YJ: **HMGCS2 Mediates Ketone Production and Regulates the Proliferation and Metastasis of Hepatocellular Carcinoma.** *Cancers (Basel)* 2019, **11**(12).
47. Tang H, Wu Y, Qin Y, Wang H, Jia Y, Yang S, Luo S, Wang Q: **Predictive significance of HMGCS2 for prognosis in resected Chinese esophageal squamous cell carcinoma patients.** *Onco Targets Ther* 2017, **10**:2553-2560.
48. Hanahan D, Weinberg RA: **Hallmarks of cancer: the next generation.** *Cell* 2011, **144**(5):646-674.
49. Abu Aboud O, Habib SL, Trott J, Stewart B, Liang S, Chaudhari AJ, Sutcliffe J, Weiss RH: **Glutamine Addiction in Kidney Cancer Suppresses Oxidative Stress and Can Be Exploited for Real-Time Imaging.** *Cancer Res* 2017, **77**(23):6746-6758.
50. Weiss RH: **Metabolomics and Metabolic Reprogramming in Kidney Cancer.** *Semin Nephrol* 2018, **38**(2):175-182.
51. Lin ZP, Belcourt MF, Cory JG, Sartorelli AC: **Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors.** *The Journal of biological chemistry* 2004, **279**(26):27030-27038.
52. Yang Y, Lin J, Guo S, Xue X, Wang Y, Qiu S, Cui J, Ma L, Zhang X, Wang J: **RRM2 protects against ferroptosis and is a tumor biomarker for liver cancer.** *Cancer Cell Int* 2020, **20**(1):587.

53. Zhuang S, Li L, Zang Y, Li G, Wang F: **RRM2 elicits the metastatic potential of breast cancer cells by regulating cell invasion, migration and VEGF expression via the PI3K/AKT signaling.** *Oncology letters* 2020, **19**(4):3349-3355.
54. Chen WX, Yang LG, Xu LY, Cheng L, Qian Q, Sun L, Zhu YL: **Bioinformatics analysis revealing prognostic significance of RRM2 gene in breast cancer.** *Bioscience reports* 2019, **39**(4).
55. Li C, Zheng J, Chen S, Huang B, Li G, Feng Z, Wang J, Xu S: **RRM2 promotes the progression of human glioblastoma.** *J Cell Physiol* 2018, **233**(10):6759-6767.
56. Jin CY, Du L, Nuerlan AH, Wang XL, Yang YW, Guo R: **High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma.** *Aging (Albany NY)* 2020, **13**(3):3518-3535.
57. Zhan Y, Jiang L, Jin X, Ying S, Wu Z, Wang L, Yu W, Tong J, Zhang L, Lou Y *et al.* **Inhibiting RRM2 to enhance the anticancer activity of chemotherapy.** *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie* 2021, **133**:110996.
58. Leite KR, Reis ST, Junior JP, Zerati M, Gomes Dde O, Camara-Lopes LH, Srougi M: **PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis.** *Diagn Pathol* 2015, **10**:189.
59. Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M *et al.* **Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.** *N Engl J Med* 2019, **380**(12):1103-1115.
60. Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthelemy P, Porta C, George S *et al.* **Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.** *N Engl J Med* 2018, **378**(14):1277-1290.

Figures

Figure 1

Volcano plots, Venn diagram and PPI network of the DEGs. (A) the volcano plots of 4 selected gene expression datasets with calculation of GEO2R. (B) In total, 382 overlapped genes in the four datasets were found dysregulated in ccRCC. (C) the PPI network of the DEGs was constructed with STING database and Cytoscape. Upregulated genes are marked in red; downregulated genes are marked in blue.

Figure 2

The most significant module of DEGs and function annotations of the genes in this module. (A) the most significant module was obtained with MCODE in Cytoscape software. (B) Cellular Component of the genes. (C) Biological Process of the genes. (D) Molecular Function of the genes. (E) KEGG pathway analysis of the genes.

Figure 3

Survival analyses of PCK1, HMGC2 and RRM2 in ccRCC with three websites. (A) Overall survival these genes with GEPIA. (B) Disease free survival of these genes with GEPIA. (C) Survival curves of these genes with UALCAN. (D) Survival curves of these genes with HPA.

Figure 4

Verification of the mRNA and protein expression of PCK1, HMGCS2 and RRM2 in ccRCC. (A) mRNA expression of these genes in ccRCC and normal tissues with GEPIA. The red box represents tumor tissues and the gray box normal tissues. The red asterisk indicates $P < 0.01$. (B) mRNA expression of these genes in different pathologic stage of ccRCC. (C) mRNA expression of these genes in renal cancer cell lines using CCLE.

Figure 5

Protein expression of PCK1, HMGCS2 and RRM2 in ccRCC and normal kidney tissues. (A) Protein expression of these genes with CPTAC datasets. (B) Protein expression of these genes with HPA immunohistochemical staining.

Figure 6

Correlation between candidate genes and tumor immune infiltration with TIMER analysis. (A) The correlation between these genes and infiltration levels of immune cells in ccRCC. (B) The relevance between candidate genes and PD-1 (CD274), PDL-1 (PDCD1) and CTLA4. (C) Drugs targeting RRM2 collected from DrugBank database.

Figure 7

Correlation between RRM2 and tumor immune infiltration using TISIDB. (A) The correlation between RRM2 expression and tumor-infiltrating lymphocytes (TILs) across 28 types of human heterogeneous cancers. (B) The correlation between RRM2 expression and TILs in ccRCC. (C) The correlation between RRM2 expression and immunoinhibitors across human heterogeneous cancers. (D) The correlation between RRM2 expression and immunoinhibitors in ccRCC.